Italia Markets open in 5 hrs 12 mins

Kinarus Therapeutics Holding AG (0QNS.L)

LSE - LSE Prezzo differito. Valuta in CHF.
Aggiungi a watchlist
0,0154+0,0154 (+84,00%)
Alla chiusura: 05:07PM BST
Schermo intero
Chiusura precedente0,0000
Aperto0,0000
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume0
Media VolumeN/D
Capitalizzazione3,252M
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-0,0010
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Kinarus Therapeutics Announces Personnel Change

    Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities. Dr Hari Kumar, Chairman of the Board of Kinarus Therapeutics Holding AG, commented: “We would like to thank Subhasis for his invaluable support of

  • GlobeNewswire

    Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting

    Basel, Switzerland, 29 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announces that its shareholders have approved all proposals by the Board of Directors at the 2023 Annual General Meeting ("AGM"), held yesterday at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland. In total, 298’358’348 shares equalling 2

  • GlobeNewswire

    Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity

    Basel, Switzerland, June 26, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today announced the signing of subordinated bridge loan agreements with existing shareholders to ensure further liquidity is available to Kinarus during the period of time required for bridging the pending transfer of funds pursuant to a CHF1.5 million convertible loan investment